Journal policiesMission and scope
MISSION AND SCOPE
The goal of Neuro-Oncology is to provide the international neuro-oncology community with high-quality, rapid publication of information in all fields. The journal welcomes submissions from throughout the world and encourages the participation of neuro-oncologists in a wide array of subspecialties. Areas covered include, but are not limited to, biochemistry and biophysics, clinical neuro-oncology, clinical therapy trials, epidemiology, imaging, immunology, medical neuro-oncology, neuropathology, molecular genetics, pediatric neuro-oncology, preclinical experimental therapeutics, retrospective clinical studies, surgical neuro-oncology, and tumor biology. Published by Oxford University Press, Neuro-Oncology is the official journal of the Society for Neuro-Oncology (SNO), the Japan Society for Neuro-Oncology, the European Association for Neuro-Oncology, and the World Federation of Neuro-Oncology Societies.
Authors should observe high standards with respect to publication ethics as set out by the Commission on Publication Ethics (COPE) and International Committee of Medical Journal Editors (ICMJE) . Falsification or fabrication of data; plagiarism, including duplicate publication of the authors’ own work without proper citation; and misappropriation of work are all unacceptable practices. Any cases of ethical misconduct are treated very seriously and will be dealt with in accordance with COPE guidelines.
All authors listed on the manuscript should have contributed significantly to the design or implementation of the experiment or the analysis and interpretation of the data. All authors should have been involved in the writing of the manuscript at the draft and any revision stages and have read and approved the final version. Any other individuals who contributed to the experiment or the writing of the manuscript should be listed in the Acknowledgment section.
Corresponding author . More than one corresponding author is permitted for each manuscript, and both authors will appear on the correspondence line on the final article. However, only one can be considered the corresponding author in the manuscript submission system; thus, only the first author entered in the system will receive automated messages, such as editors’ decisions and page proofs.
Authorship Requirements . For guidelines on authorship, please refer to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals [PDF], formulated by the International Committee of Medical Journal Editors. The cover letter should state that all authors have seen and approved the manuscript.
By submitting your manuscript to the journal, it is understood that it is an original manuscript, is unpublished work, and is not under consideration elsewhere.
Authorship and "Umbrella" groups
Many large collaborative studies are organized under a group name that represents all the participants. All articles must have at least one named individual as author. Authors who wish to acknowledge the umbrella group from which the data originate should list the authors of the article, followed by "on behalf of the [GROUP NAME]". If necessary, the names of the participants may be listed in the Acknowledgements section.
Conflict of interest
At the point of submission, each author should reveal any financial interests or connections, direct or indirect, or other situations that might raise the question of bias in the work reported or the conclusions, implications, or opinions stated--including pertinent commercial or other sources of funding for the individual authors or for the associated departments or organizations, personal relationships, or direct academic competition. When considering whether you should declare a conflicting interest or connection, please consider the conflict of interest test: Is there any arrangement that would embarrass you or any of your co-authors if it was to emerge after publication and you had not declared it?
If the manuscript is published, Conflict of Interest information, including if none was declared, will be communicated in a statement in the published paper.
Any changes made to the list of conflicts after the paper is accepted must be submitted in writing, signed by the appropriate authors (that is, the corresponding author and the author for whom the conflict exists), to the Neuro-Oncology editorial office . Publication of manuscripts will be withheld until all such written approvals are received. Neuro-Oncology accepts no responsibility for such changes.
When reporting animal experiments, authors should indicate whether the institution’s, national research council’s, or any other law on the care and use of laboratory animals was followed.
When reporting on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the Helsinki Declaration (1964, amended most recently in 2008) of the World Medical Association. Manuscripts should include a statement that the patient’s written consent was obtained and any information, including illustrations, should be as anonymized as far as possible. Authors should indicate that the design of the work has been approved by local ethical committees or that it conforms to standards currently applied in the country of origin. The name of the authorizing body should be stated in the paper.
Registering clinical trials
In accordance with the Clinical Trial Registration Statement from the International Committee of Medical Journal Editors (ICMJE) , all clinical trials published in the journal must be registered in a public trials registry at or before the onset of participant enrolment.
The registry must be accessible to the public at no charge, searchable, open to all prospective registrants, managed by a not-for-profit organization, and include all the necessary information as specified by the ICMJE . A list of recommended registries can be found on the ICMJE website . Results posted in the same clinical trials registry in which the primary registration resides will not be considered prior publication if they are presented in the form of a brief abstract (<500 words or less) or a table.
Authors are requested to provide the exact URL and unique identification number for the trial registration at the time of submission. This information will be published in the article, and we ask that you include the URL and identification number on the title page of your manuscript.
Reporting clinical trials
Clinical trials should comply with the Consolidated Standards of Reporting Trials Statement (CONSORT). Authors reporting on randomized clinical trials should consult the CONSORT checklist when preparing their manuscripts. All trial data will be evaluated in accordance with the rules and checklist of the CONSORT statement.
For information about this journal's policy, please visit our Author Self-Archiving policy page .
The mention of trade names or commercial products or organizations and the inclusion of advertisements in Neuro-Oncology does not imply endorsement by the Society, the editors, the editorial board, Oxford University Press, or the organization to which the authors are affiliated. The editors and publishers have taken all reasonable precautions to verify drug names and doses, the results of experimental work, and clinical findings published in Neuro-Oncology . The ultimate responsibility for the use and dosage of drugs mentioned in Neuro-Oncology and in the interpretation of published material lies with the medical practitioner, and the editors and publishers cannot accept liability for damages arising from any errors or omissions in Neuro-Oncology . Please inform the editors of any errors.
The opinions expressed in Neuro-Oncology are those of the authors and contributors and do not necessarily reflect those of the Society, the editors, the editorial board, Oxford University Press, or the organization to which the authors are affiliated.